Related references
Note: Only part of the references are listed.Traditional and New Influenza Vaccines
Sook-San Wong et al.
CLINICAL MICROBIOLOGY REVIEWS (2013)
Vaccine delivery carriers: Insights and future perspectives
J. F. Correia-Pinto et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2013)
Comparison of immunogenicity and reactogenicity of split versus subunit influenza vaccine in Korean children aged 6-35 months
Yun Kyung Kim et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2013)
Antibodies and their receptors: different potential roles mucosal defense
Rachel E. Horton et al.
FRONTIERS IN IMMUNOLOGY (2013)
Intranasal immunization with live attenuated influenza vaccine plus chitosan as an adjuvant protects mice against homologous and heterologous virus challenge
Xueliang Wang et al.
ARCHIVES OF VIROLOGY (2012)
Intranasal Immunization with a Formalin-Inactivated Human Influenza A Virus Whole-Virion Vaccine Alone and Intranasal Immunization with a Split-Virion Vaccine with Mucosal Adjuvants Show Similar Levels of Cross-Protection
Shigefumi Okamoto et al.
CLINICAL AND VACCINE IMMUNOLOGY (2012)
The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine
Signe C. Svindland et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2012)
Chitosan-based drug nanocarriers: Where do we stand?
Marcos Garcia-Fuentes et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Chitosan Microparticles and Nanoparticles as Biocompatible Delivery Vehicles for Peptide and Protein-Based Immunocontraceptive Vaccines
Brendon Y. Chua et al.
MOLECULAR PHARMACEUTICS (2012)
Dendritic Cell Targeted Chitosan Nanoparticles for Nasal DNA Immunization against SARS CoV Nucleocapsid Protein
Dharmendra Raghuwanshi et al.
MOLECULAR PHARMACEUTICS (2012)
Oily adjuvants and autoimmunity: now time for reconsideration?
M. Whitehouse
LUPUS (2012)
Enhancement of the Immunogenicity and Protective Efficacy of a Mucosal Influenza Subunit Vaccine by the Saponin Adjuvant GPI-0100
Heng Liu et al.
PLOS ONE (2012)
Intranasal immunisation of mice against Streptococcus equi using positively charged nanoparticulate carrier systems
L. Figueiredo et al.
VACCINE (2012)
Clinical and socioeconomic impact of seasonal and pandemic influenza in adults and the elderly
Roberto Gasparini et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
Particulate vaccines: on the quest for optimal delivery and immune response
Marie-Luce De Temmerman et al.
DRUG DISCOVERY TODAY (2011)
Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes
Samuele Calabro et al.
VACCINE (2011)
Chitosan-based delivery systems for protein therapeutics and antigens
Maryam Amidi et al.
ADVANCED DRUG DELIVERY REVIEWS (2010)
Chitosan-based formulations for delivery of DNA and siRNA
Shirui Mao et al.
ADVANCED DRUG DELIVERY REVIEWS (2010)
Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles
Chunbai He et al.
BIOMATERIALS (2010)
Vaccination, squalene and anti-squalene antibodies: Facts or fiction?
Giuseppe Lippi et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2010)
Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant
Zhiwei Sui et al.
VACCINE (2010)
Ionically crosslinked chitosan/tripolyphosphate nanoparticles for oligonucleotide and plasmid DNA delivery
Noemi Csaba et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2009)
Low molecular weight chitosan in DNA vaccine delivery via mucosa
Xiaorong Yang et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2009)
Pharmaceutical Aspects of Intranasal Delivery of Vaccines Using Particulate Systems
Sameer Sharma et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant
Timo Vesikari et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2009)
Physicochemical and Immunological Characterization of N,N,N-Trimethyl Chitosan-Coated Whole Inactivated Influenza Virus Vaccine for Intranasal Administration
Niels Hagenaars et al.
PHARMACEUTICAL RESEARCH (2009)
Poly(γ-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice
Shigefumi Okamoto et al.
VACCINE (2009)
Human Muscle Cells Express the Costimulatory Molecule B7-H3, Which Modulates Muscle-Immune Interactions
Anne Waschbisch et al.
ARTHRITIS AND RHEUMATISM (2008)
Influenza hemagglutinin vaccine with poly (γ-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity
Shigefumi Okamoto et al.
VACCINE (2007)
Should a new tuberculosis vaccine be administered intranasally?
Gunilla Kallenius et al.
TUBERCULOSIS (2007)
N-Trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination:: Biological properties and immunogenicity in a mouse model
Maryam Amidi et al.
VACCINE (2007)
Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children
Kathleen M. Neuzil et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Mucosal vaccines: the promise and the challenge
MR Neutra et al.
NATURE REVIEWS IMMUNOLOGY (2006)
The basics and underlying mechanisms of mucoadhesion
JD Smart
ADVANCED DRUG DELIVERY REVIEWS (2005)
Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery
Q Gan et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2005)
Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model
C Foged et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2005)
Role of IgA in the defense against respiratory infections IgA deficient mice exhibited increased susceptibility to intranasal infection with Mycobacterium bovis BCG
A Rodríguez et al.
VACCINE (2005)
Nanoparticles as carriers for nasal vaccine delivery
M Köping-Höggård et al.
EXPERT REVIEW OF VACCINES (2005)
Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery
HO Alpar et al.
ADVANCED DRUG DELIVERY REVIEWS (2005)
Transmucosal macromolecular drug delivery
C Prego et al.
JOURNAL OF CONTROLLED RELEASE (2005)
Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery
T Nagamoto et al.
PHARMACEUTICAL RESEARCH (2004)
Nalt- versus Peyer's-patch-mediated mucosal immunity
H Kiyono et al.
NATURE REVIEWS IMMUNOLOGY (2004)
Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice
A Vila et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2004)
The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines
KL Nichol
VACCINE (2003)
Nasal drug delivery - possibilities, problems and solutions
L Illum
JOURNAL OF CONTROLLED RELEASE (2003)
Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles
YM Xu et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2003)
Chitosan and its derivatives in mucosal drug and vaccine delivery
IM van der Lubben et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2001)
Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza
KG Nicholson et al.
LANCET (2001)
Share Paper
